An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Hematologic Malignancies.
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Afuresertib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 10 Jul 2018 Status changed from recruiting to completed.
- 22 Jun 2018 This trial has been Discontinued in Ireland (end date: 2018-06-18)
- 07 May 2018 Status changed from active, no longer recruiting to recruiting.